Alan Cassels

Alan Cassels

Auto-generated profile, based on publicly available information

Alan Cassels

University of Victoria, Victoria, Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Trials
Verified
Journal Article
Open access
PDF file
DMDee Mangin
Dee Mangin
LLLarkin Lamarche
Larkin Lamarche
GAGina Agarwal
Gina Agarwal
HBHoan Linh Banh
Hoan Linh Banh
NBNaomi Dore Brown
Naomi Dore Brown
LTLehana Thabane
Lehana Thabane
Background: Polypharmacy in older adults can be associated with negative outcomes including falls, impaired cognition, reduced quality of life, and general and functional decline. It is not clear to what extent these are reversible if the number of medications is reduced. Primary care does not have a systematic approach for reducing inappropriate polypharmacy, and there are few, if any, approaches that account for the patient’s priorities and preferences. The primary objective of this study is to test the effect of TAPER (Team Approach to Polypharmacy Evaluation and Reduction), a structured operationalized clinical pathway focused on reducing inappropriate polypharmacy. TAPER integrates evidence tools for identifying potentially inappropriate medications, tapering, and monitoring guidance and explicit elicitation of patient priorities and preferences. We aim to determine the effect of TAPER on the number of medications (primary outcome) and health-related outcomes associated with polypharmacy in older adults.Methods: We designed a multi-center randomized controlled trial, with the lead implementation site in Hamilton, Ontario. Older adults aged 70 years or older who are on five or more medications will be eligible to participate. A total of 360 participants will be recruited. Participants will be assigned to either the control or intervention arm. The intervention involves a comprehensive multidisciplinary medication review by pharmacists and physicians in partnership with patients. This review will be focused on reducing medication burden, with the assumption that this will reduce the risks and harms of polypharmacy. The control group is a wait list, and control patients will be given appointments for the TAPER intervention at a date after the final outcome assessment. All patients will be followed up and outcomes measured in both groups at baseline and 6 months.Discussion: Our trial is unique in its design in that it aims to introduce an operationalized structured clinical pathway aimed to reduce polypharmacy in a primary care setting while at the same time recording patient’s goals and priorities for treatment.Trial registration: ClinicalTrials.govNCT02942927. First registered on October 24, 2016.

20 December 2016 in European Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
ACAlan Cassels
Alan Cassels

22 April 2008
Verified
Journal Article
Open access
ACAlan Cassels
Alan Cassels
JLJoel Lexchin
Joel Lexchin

1 March 2018 in Health Policy
Verified
Journal Article
Closed access
EREllen Reynolds
Ellen Reynolds
LGLine Guénette
Line Guénette
JLJoel Lexchin
Joel Lexchin
ACAlan Cassels
Alan Cassels
MWMichael S. Wilkes
Michael S. Wilkes
BMBarbara Mintzes
Barbara Mintzes


18 July 2019 in CMAJ Open
Verified
Journal Article
Closed access
ACAlan Cassels
Alan Cassels
MLMichael R. Law
Michael R. Law
Most private drug plans in Canada do not use a formulary, which leads to suboptimal drug use. We studied the impact of the adoption of the public formulary by a large private health benefits plan in British Columbia. We studied the impact of a change by members of the BC Hospital Employees' Union to have their private drug plan mirror the public formulary as of June 2013. With data from Pacific Blue Cross, we conducted a before-and-after descriptive study using interrupted time-series analysis to study changes in covered drug costs and use for 18 months preceding and following the change. Our cohort averaged 66 000 plan members and dependents over our study period. Following the implementation of the formulary, the number of prescriptions covered by the plan declined by 0.46 prescriptions per member per month (95% confidence interval -0.50 to -0.42), a decline of 23.8% at 1 year. This decreased plan spending by $1.32 million over the 18 months after the coverage change, a 49.7% decline. The adoption of the public formulary by a large private drug plan in BC substantially reduced drug plan expenditures and the volume of prescriptions paid for by the plan. Overall, these results suggest that carefully designed formulary changes could substantially reduce spending by private-sector drug plans on drugs that have more cost-effective therapeutic alternatives.